Drugmaker Wockhardt Ltd,. reported a sharp turnaround in its second-quarter earnings for FY26, posting a profit after tax of Rs 82 crore, compared to a loss of Rs 108 crore in the previous quarter.
The company reported a net loss of Rs 16 crore.
The pharmaceutical and biotech company also saw a 58% sequential jump in EBITDA, which rose to Rs 160 crore from Rs 101 crore, driven by improved operating performance and strong growth in its biotech segment.
Revenue for the quarter stood at Rs 782 crore, up from Rs 738 crore in Q1. EBITDA margins improved to 20.5%, up from 13.7% in the previous quarter.
Shares of Wochardt rose 10.43% to close at Rs. 1414.95 on BSE on Monday.
The company’s biosimilars business contributed Rs 154 crore, growing 42% quarter-on-quarter, with strong momentum in emerging markets such as Thailand, Egypt, Algeria, and Latin America. Wockhardt also highlighted new partnerships in Russia and Malaysia, and announced upcoming launches of insulin analogs to strengthen its leadership in diabetes care.
Wockhardt’s international business continues to dominate its revenue mix, with 79% of global revenues coming from overseas markets. The UK business contributed Rs 313 crore in Q2, growing 4% year-on-year, while the Irish business surged 40% to Rs 59 crore.
Update on NCE pipeline
The quarter also marked a major milestone for Wockhardt’s novel antibiotic pipeline. In September, the company filed a New Drug Application (NDA) with the USFDA for Zaynich (WCK 5222), a novel antibacterial agent targeting complicated urinary tract infections (cUTI), including pyelonephritis caused by multidrug-resistant Gram-negative bacteria. This is the first-ever NDA submission to the U.S. FDA for a drug fully discovered and developed by an Indian pharmaceutical company.
“Zaynich represents a landmark moment for Indian innovation in global drug discovery,” the company said in its statement. The drug has also received Breakthrough Medicines Program designation from the Saudi FDA and has been filed in India.
Wockhardt said its other drug MIQNAF (Nafithromycin), approved in India in May 2025, with Phase 3 CABP study published in The Lancet. It has been included in the Clinical Infectious Disease Society’s 2025 guidelines for treating resistant pathogens.
Wockhardt said its WCK 6777 (Ertapenem-Zidebactam) has received Fast Track designation from the US FDA for cUTI and cIAI.
WCK 4282 (FOVISCU), which completed Phase 2/3 enrollment for cUTI. The drug is positioned as a first-line empirical therapy against ESBL infections, aiming to reduce dependence on carbapenems and combat antimicrobial resistance.
Wockhardt also reported strong intellectual property activity, with seven new patents filed and five granted during the quarter, bringing its total patent count to 858.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
